Alembic Pharmaceuticals Limited has informed the Exchange that Board of Directors at its meeting held on May 06, 2025, recommended Final Dividend of Rs. 11 per equity share.
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.5 pts less than Nifty Microcap 250 and 0.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Alembic Pharmaceuticals reported FY25 consolidated revenue of Rs. 6,672 crore, up about 7% from Rs. 6,229 crore last year, while standalone revenue rose around 2.7% to Rs. 6,033 crore. However, standalone net profit fell sharply by about 24% to Rs. 503 crore and consolidated PAT dipped roughly 5% to Rs. 583 crore, with EPS dropping to Rs. 29.68 from Rs. 31.33. The company booked a one-time exceptional gain of Rs. 12.87 crore from the final settlement of the October 2023 Sikkim flood insurance claim. Operating margin on a standalone basis compressed from 17.5% to 15.7%, indicating cost pressure. The board maintained the final dividend at Rs. 11 per share (550%) for the second year in a row and appointed KKC & Associates LLP as the new statutory auditor for five years, replacing retiring auditor K.C. Mehta & Co. LLP. The auditor issued an unmodified (clean) opinion on the results.
Mixed bag for shareholders – revenue grew modestly but profitability and margins came under pressure, especially on the standalone side, which could weigh on the stock in the short term. The maintained Rs. 11 dividend provides some income comfort, while the auditor change is a routine retirement-related transition and not a red flag.